https://investors.inhibitortx.com/ https://investors.inhibitortx.com/news-events/press-releases https://investors.inhibitortx.com/news-events/ir-calendar https://investors.inhibitortx.com/news-events/presentations https://investors.inhibitortx.com/news-events/email-alerts https://investors.inhibitortx.com/company-information https://investors.inhibitortx.com/company-information/contacts https://investors.inhibitortx.com/company-information/faq https://investors.inhibitortx.com/financial-information/financial-results https://investors.inhibitortx.com/financial-information/income-statement https://investors.inhibitortx.com/financial-information/balance-sheet https://investors.inhibitortx.com/financial-information/cash-flow https://investors.inhibitortx.com/stock-data/quote-chart https://investors.inhibitortx.com/stock-data/historical-data https://investors.inhibitortx.com/sec-filings/all-sec-filings https://investors.inhibitortx.com/sec-filings/annual-reports https://investors.inhibitortx.com/sec-filings/quarterly-reports https://investors.inhibitortx.com/sec-filings/section-16-filings https://investors.inhibitortx.com/corporate-governance https://investors.inhibitortx.com/corporate-governance/board-committees https://investors.inhibitortx.com/corporate-governance/governance-documents https://investors.inhibitortx.com/news-events/press-releases/detail/11/inhibitor-therapeutics-provides-clinical-formulation-and-ip-update-on-itraconazole-program-for-gorlin-syndrome https://investors.inhibitortx.com/news-events/press-releases/detail/10/inhibitor-therapeutics-inc-provides-update-on-its-clinical-development-plan https://investors.inhibitortx.com/news-events/press-releases/detail/5/introducing-inhibitor-therapeutics-inc-new-scientific-advisory-board https://investors.inhibitortx.com/news-events/press-releases/detail/6/inhibitor-therapeutics-inc-exclusive-license-with-johns-hopkins-university https://investors.inhibitortx.com/news-events/press-releases/detail/7/inhibitor-therapeutics-receives-prostate-cancer-ind-clearance-from-fda https://investors.inhibitortx.com/news-events/press-releases/detail/8/inhibitor-therapeutics-submits-investigational-new-drug-application-for-treatment-of-patients-with-late-stage-prostate-cancer https://investors.inhibitortx.com/news-events/press-releases/detail/9/inhibitor-therapeutics-appoints-dr-debra-peattie-to-its-board-of-directors https://investors.inhibitortx.com/privacy-policy https://investors.inhibitortx.com/disclaimer https://investors.inhibitortx.com/sitemap